Skip to main content
NCBI home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1997 Sep 15;25(18):3584–3589. doi: 10.1093/nar/25.18.3584

A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides.

J R Deverre 1, V Boutet 1, D Boquet 1, E Ezan 1, J Grassi 1, J M Grognet 1
PMCID: PMC146941  PMID: 9278477

Abstract

An enzyme competitive hybridization assay was developed and validated for determination of mouse plasma concentrations of a 15mer antisense phosphodiester oligodeoxyribonucleotide and of two phosphorothioate analogs. Assays were performed in 96-well microtiter plates. The phosphodiester sense sequence was covalently bound to the microwells. The 5'-biotinylated antisense sequence was used as tracer. The principle of the assay involves competitive hybridization of tracer and antisense nucleotide to the solid phase-immobilized sense oligonucleotide. Solid phase- bound tracer oligonucleotide was assayed after reaction with a streptavidin-acetylcholinesterase conjugate, using the colorimetric method of Ellman. As in competitive enzyme immunoassays, coloration was inversely related to the amount of analyte initially present in the sample. The limit of quantification was 900 pM for phosphodiester antisense oligonucleotide using a 100 microl volume of plasma without extraction. Cross-reactivity was negligible after a four base deletion in either the 3'or 5'position. The assay was simple and sensitive, suitable for in vitro screening of oligonucleotide hybridization potency in biological fluids and for measuring the plasma pharmacokinetics of phosphorothioate and phosphodiester sequences.

Full Text

The Full Text of this article is available as a PDF (94.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal S., Temsamani J., Galbraith W., Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7–16. doi: 10.2165/00003088-199528010-00002. [DOI] [PubMed] [Google Scholar]
  2. Chevrier D., Rasmussen S. R., Guesdon J. L. PCR product quantification by non-radioactive hybridization procedures using an oligonucleotide covalently bound to microwells. Mol Cell Probes. 1993 Jun;7(3):187–197. doi: 10.1006/mcpr.1993.1028. [DOI] [PubMed] [Google Scholar]
  3. Crooke R. M. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des. 1991 Dec;6(6):609–646. [PubMed] [Google Scholar]
  4. Crooke S. T., Graham M. J., Zuckerman J. E., Brooks D., Conklin B. S., Cummins L. L., Greig M. J., Guinosso C. J., Kornbrust D., Manoharan M. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther. 1996 May;277(2):923–937. [PubMed] [Google Scholar]
  5. Nikiforov T. T., Rogers Y. H. The use of 96-well polystyrene plates for DNA hybridization-based assays: an evaluation of different approaches to oligonucleotide immobilization. Anal Biochem. 1995 May 1;227(1):201–209. doi: 10.1006/abio.1995.1271. [DOI] [PubMed] [Google Scholar]
  6. Pradelles P., Grassi J., Chabardes D., Guiso N. Enzyme immunoassays of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate using acetylcholinesterase. Anal Chem. 1989 Mar 1;61(5):447–453. doi: 10.1021/ac00180a014. [DOI] [PubMed] [Google Scholar]
  7. Putnam D. A. Antisense strategies and therapeutic applications. Am J Health Syst Pharm. 1996 Jan 15;53(2):151–183. doi: 10.1093/ajhp/53.2.151. [DOI] [PubMed] [Google Scholar]
  8. Rasmussen S. R., Larsen M. R., Rasmussen S. E. Covalent immobilization of DNA onto polystyrene microwells: the molecules are only bound at the 5' end. Anal Biochem. 1991 Oct;198(1):138–142. doi: 10.1016/0003-2697(91)90518-x. [DOI] [PubMed] [Google Scholar]
  9. Sands H., Gorey-Feret L. J., Cocuzza A. J., Hobbs F. W., Chidester D., Trainor G. L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932–943. [PubMed] [Google Scholar]
  10. Shaw J. P., Fishback J. A., Cundy K. C., Lee W. A. A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum. Pharm Res. 1995 Dec;12(12):1937–1942. doi: 10.1023/a:1016243923195. [DOI] [PubMed] [Google Scholar]
  11. Srinivasan S. K., Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal. 1995;9(2):129–137. doi: 10.1002/jcla.1860090210. [DOI] [PubMed] [Google Scholar]
  12. Temsamani J., Kubert M., Agrawal S. A rapid method for quantitation of oligodeoxynucleotide phosphorothioates in biological fluids and tissues. Anal Biochem. 1993 Nov 15;215(1):54–58. doi: 10.1006/abio.1993.1553. [DOI] [PubMed] [Google Scholar]
  13. de Serres M., McNulty M. J., Christensen L., Zon G., Findlay J. W. Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study. Anal Biochem. 1996 Jan 15;233(2):228–233. doi: 10.1006/abio.1996.0033. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES